Half-dose Pfizer COVID booster nearly as effective as full dose with fewer side effects

Study compares the half-dose and full-dose Pfizer-BioNTech BNT162b2 COVID-19 booster in adults previously vaccinated with ChAdOx1, BBIBP-CorV, or Gam-COVID-Vac. It finds that the half-dose booster has fewer side effects and maintains similar immunogenicity, offering a viable option for booster vaccination strategies.

Can investing in infectious disease pay off? Vir Biotechnology’s tightrope walk shows it’s a struggle

Nearly a decade ago, venture capitalist Bob Nelsen called industry veteran Vicki Sato to pitch her on launching a large company dedicated to tackling the

April 15, 2024

Transgender adults in rural US more likely to have cardiovascular disease risk factors

Transgender adults living in the rural Appalachian area of the U.S., were more likely to have cardiovascular disease risk factors, like tobacco use, obesity and

November 6, 2023

Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Company’s moratorium and changes to its Executive Committee. – Biotech Investments

Spexis AG / Key word(s): Miscellaneous 22-Jul-2024 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely

July 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.